PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social Infrastructure
- PMID: 34626265
- PMCID: PMC8501360
- DOI: 10.1007/s10461-021-03488-2
PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social Infrastructure
Abstract
Pre-exposure prophylaxis (PrEP) is a medication that prevents HIV acquisition, yet PrEP uptake has been low among people who inject drugs. Stigma has been identified as a fundamental driver of population health and may be a significant barrier to PrEP care engagement among PWID. However, there has been limited research on how stigma operates in rural and urban settings in relation to PrEP. Using in-depth semi-structured qualitative interviews (n = 57) we explore PrEP continuum engagement among people actively injecting drugs in rural and urban settings. Urban participants had more awareness and knowledge. Willingness to use PrEP was similar in both settings. However, no participant was currently using PrEP. Stigmas against drug use, HIV, and sexualities were identified as barriers to PrEP uptake, particularly in the rural setting. Syringe service programs in the urban setting were highlighted as a welcoming space where PWID could socialize and therefore mitigate stigma and foster information sharing.
Keywords: HIV; Persons who inject drugs (PWID); Pre-exposure prophylaxis (PrEP); Rural; Social infrastructure; Stigma; Third places; Urban.
© 2021. The Author(s).
Similar articles
-
Perspectives on pre-exposure prophylaxis for people who inject drugs in the context of an hiv outbreak: A qualitative study.Int J Drug Policy. 2021 Feb;88:103033. doi: 10.1016/j.drugpo.2020.103033. Epub 2020 Nov 26. Int J Drug Policy. 2021. PMID: 33249313
-
Examining HIV pre-exposure prophylaxis (PrEP) acceptability among rural people who inject drugs: predictors of PrEP interest among syringe service program clients.AIDS Care. 2024 Dec;36(12):1858-1868. doi: 10.1080/09540121.2024.2390067. Epub 2024 Aug 13. AIDS Care. 2024. PMID: 39137923
-
Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.Harm Reduct J. 2018 Nov 12;15(1):55. doi: 10.1186/s12954-018-0263-5. Harm Reduct J. 2018. PMID: 30419926 Free PMC article.
-
The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review.AIDS Behav. 2021 May;25(5):1490-1506. doi: 10.1007/s10461-020-02988-x. AIDS Behav. 2021. PMID: 32749627 Free PMC article.
-
Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery.Harm Reduct J. 2023 Feb 13;20(1):16. doi: 10.1186/s12954-023-00729-6. Harm Reduct J. 2023. PMID: 36782321 Free PMC article. Review.
Cited by
-
Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.Harm Reduct J. 2022 Dec 3;19(1):132. doi: 10.1186/s12954-022-00718-1. Harm Reduct J. 2022. PMID: 36463214 Free PMC article. Clinical Trial.
-
Determinants of PrEP Uptake, Intention and Awareness in the Netherlands: A Socio-Spatial Analysis.Int J Environ Res Public Health. 2022 Jul 20;19(14):8829. doi: 10.3390/ijerph19148829. Int J Environ Res Public Health. 2022. PMID: 35886681 Free PMC article.
-
Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.Harm Reduct J. 2024 Mar 26;21(1):69. doi: 10.1186/s12954-024-00983-2. Harm Reduct J. 2024. PMID: 38532395 Free PMC article. Clinical Trial.
-
Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users.AIDS Behav. 2025 Jun 17. doi: 10.1007/s10461-025-04749-0. Online ahead of print. AIDS Behav. 2025. PMID: 40524110
-
Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.Subst Use Misuse. 2022;57(7):1144-1153. doi: 10.1080/10826084.2022.2064509. Epub 2022 Apr 21. Subst Use Misuse. 2022. PMID: 35443862 Free PMC article.
References
-
- Choopanya K, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2013;381(9883):2083–2090. - PubMed
-
- Martin M, et al. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS. 2015;29(7):819–824. - PubMed
MeSH terms
Substances
Grants and funding
- UL1TR001445/NIH Clinical and Translational Science Awards Program
- P30 DA011041/DA/NIDA NIH HHS/United States
- T32 DA007233-31/DA/NIDA NIH HHS/United States
- K01DA053159/DA/NIDA NIH HHS/United States
- K01 DA053159/DA/NIDA NIH HHS/United States
- 4UH3DA044829-03/DA/NIDA NIH HHS/United States
- P30DA01104/DA/NIDA NIH HHS/United States
- UL1 TR001445/TR/NCATS NIH HHS/United States
- R25DA026401/DA/NIDA NIH HHS/United States
- P30DA01104/DA/NIDA NIH HHS/United States
- P30DA01104/DA/NIDA NIH HHS/United States
- P30DA01104/DA/NIDA NIH HHS/United States
- P30DA01104/DA/NIDA NIH HHS/United States
- T32 DA007233-31/DA/NIDA NIH HHS/United States
- T32 DA007233-31/DA/NIDA NIH HHS/United States
- R25DA026401/DA/NIDA NIH HHS/United States
- 4UH3DA044829-03/DA/NIDA NIH HHS/United States
- 4UH3DA044829-03/DA/NIDA NIH HHS/United States
- 4UH3DA044829-03/DA/NIDA NIH HHS/United States
- 4UH3DA044829-03/DA/NIDA NIH HHS/United States
- K01DA053159/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous